The authors wish to make the following correction to their paper [...]

Bachmann, Martin F.

Cabral-Miranda, Gustavo

Heath, Matthew D.

Kramer, Matthias F.

Lim, Stephanie M.

Martina, Byron E. E.

Mohsen, Mona O.

Pobelov, Ilya V.

Roesti, Elisa S.

Skinner, Murray A.

English

Bern Open Repository and Information System (BORIS)

CorrectionCorrection: Zika Virus-Derived E-DIII ProteinDisplayed on Immunologically Optimized VLPsInduces Neutralizing Antibodies without CausingEnhancement of Dengue Virus Infection. Vaccines 2019,7, 72Gustavo Cabral-Miranda 1,2,*, Stephanie M. Lim 3, Mona O. Mohsen 1,2 , Ilya V. Pobelov 4,Elisa S. Roesti 2, Matthew D. Heath 5, Murray A. Skinner 5, Matthias F. Kramer 5 ,Byron E. E. Martina 3,6 and Martin F. Bachmann 1,2,*1 The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and MolecularPhysiology (CCMP), University of Oxford, Oxford OX1 2JD, UK; mmohsen@qf.org.qa2 Immunology, RIA, Inselspital, University of Bern, 3010 Bern, Switzerland; elisa.roesti@dbmr.unibe.ch3 Artemis Bio-Support, Molengraaffsingel, 2629 Delft, The Netherlands; s.lim@artemisonehealth.com (S.M.L.);b.martina@artemisonehealth.com (B.E.E.M.)4 Department of Chemistry and Biochemistry, University of Bern, 3010 Bern, Switzerland;ilya.pobelov@dcb.unibe.ch5 Bencard Adjuvant Systems, Worthing BN14 8SA, UK; matthew.heath@allergytherapeutics.com (M.D.H.);Murray.Skinner@allergytherapeutics.com (M.A.S.); KramerM@bencard.com (M.F.K.)6 Department of Viroscience, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands* Correspondence: gcabral.miranda@gmail.com (G.C.-M.); martin.bachmann@me.com (M.F.B.);Tel.: +41-(0)-31-632-60-45 (G.C.-M.); Fax: +41-(0)31-381-57-35 (G.C.-M.)Received: 13 February 2020; Accepted: 19 February 2020; Published: 20 February 2020The authors wish to make the following correction to their paper [1].The same image was mistakenly selected for Figures 2 and 3. The image became replaced as yousee in Figure 3 below.   Vaccines 2020, 8, 94; doi:10.3390/vaccines8010094 www.mdpi.com/journal/vaccines Correction Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72 Gustavo Cabral-Miranda 1,2,*, Stephanie M. Lim 3, Mona O. Mohsen 1,2, Ilya V. Pobelov 4,  Elisa S. Roesti 2, Matthew D. Heath 5, Murray A. Skinner 5, Matthias F. Kramer 5,  Byron E.E Martina 3,6 and Martin F. Bachmann 1,2,* 1 The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), University of Oxford, Oxford OX1 2J , UK; mmohsen@qf.org.qa 2 Immunology, RIA, Ins lspital, University of Bern, 3010 Bern, Switzerland; elisa.roesti@dbmr.unibe.ch 3 A emis Bio-Support, Molengraaffsingel, 2629 Delft, The Neth rlands;  s.lim@artemisonehealth.com (S.M.L.); b.martina@artemisonehealth.com (B.E.E.M.) 4 Department of Chemistry and Biochemistry, University of Bern, 3010 Bern, Switzerland 5 Bencard Adjuv nt Systems, Worthing BN14 8S , UK; ilya.pobelov@d b.unibe.ch (M.D.H.); Murray.Skinner@allergytherapeutics.com (M.A.S.)  6 Department of Viroscience, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands * Correspondence: gcabral.miranda@gmail.com (G.C.-M.); martin.bachmann@me.com (M.F.B.);  Tel.: +41-(0)-31-632-60-45 (G.C.-M.); Fax: +41-(0)31-381-57-35 (G.C.-M.) R ceived: 3 May 2019; Accepted: 15 July 2019; Published: 20 February 2020  The authors wish to make the following correction to their paper [1].  The sa e image was mistakenly selected f  res 2 and 3. The image b came replaced as you see in Figure 3 below.   Figure 2. CuMVtt-EDIII formulated in DOPS indices highest total IgG responses. The figure shows IgGs level of three different groups of mice vaccinated with EDIII alone formulated in phosphate-buffered saline (PBS), with vaccine formulated by coupling EDIII to VLP (CuMVtt-EDIII) or formulating CuMVtt-EDIII plus DOPS adjuvant. The assessment was done with sera collected three weeks after each vaccination. The results were analyzed using GraphPad Prism software applied to assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in Figure 2. CuMVtt-EDIII formulated in DOPS indices highest total IgG responses. The fig s IgGslevel of three different groups of mice vacc nated with EDIII alone formulated in phosphate-bufferedsaline (PBS), with vaccine formulated by coupling EDIII to VLP (CuMVtt-EDIII) or formulatingCuMVtt-EDIII plus DOPS adjuvant. The assessment was done ith sera collected three weeks aftereach vaccination. The results were analyzed using GraphPad Prism software applied to assess themeans of three groups by one-way analysis of variance (ANOVA). The values observed in the negativecontrol group (vaccinated with only PBS) were subtracted from the titers of the other experimentalgroups. Note: * p < 0.01, ** p < 0.001, *** p < 0.0001.Vaccines 2020, 8, 94; doi:10.3390/vaccines8010094 www.mdpi.com/journal/vaccinessource: https://doi.org/10.7892/boris.148000 | downloaded: 27.12.2020Vaccines 2020, 8, 94 2 of 2Vaccines 2020, 8, 94 2 of 2  the negative control group (vaccinated with only PBS) were subtracted from the titers of the other experimental groups. Note: * p < 0.01, ** p < 0.001, *** p < 0.0001.  Figure 3. Subclasses of IgG. The figure shows the specific subclasses of IgG induced by each vaccine from samples collected three weeks after the third vaccination (Day 63). The group of mice vaccinated with only EDIII predominantly produced IgG1 while EDIII coupled to VLP (CuMVtt-EDIII) also induced IgG2a and IgG2b. When DOPS adjuvant was ad-mixed, this skewing towards IgG2a and b was even more pronounced. The results were analyzed using GraphPad Prism software applied to assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in the negative control group were subtracted from the titers of the other experimental groups. Note: **  p < 0.001, *** p < 0.0001. Conflicts of Interest The authors declare that they have no conflict of interest. Reference 1. Cabral-Miranda, G.; Lim, S.M.; Mohsen, M.O.; Pobelov, I.V.; Roesti, E.S.; Heath, M.D.; Skinner, M.A.; Kramer, M.F.; Martina, B.E.E.; Bachmann, M.F. Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72.  © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).  Figure 3. Subclasses of IgG. The figure shows the specific subclasses of IgG induced by each vaccinefrom samples collected three weeks after the third vaccination (Day 63). The group of mice vaccinatedwith only EDIII predominantly produced IgG1 while EDIII coupled to VLP (CuMVtt-EDIII) alsoinduced IgG2a and IgG2b. When DOPS adjuvant was ad-mixed, this skewing towards IgG2a and bwas even more pronounced. The results were analyzed using GraphPad Prism software applied toassess the means of three groups by one-way analysis of variance (ANOVA). The values observed inthe negative control group were subtracted from the titers of the other experimental groups. Note: ** p< 0.001, *** p < 0.0001.fl ts of Interest: The authors declare that they have no conflict of interest.Reference1. Cabral-Miranda, G.; Lim, S.M.; Mohsen, M.O.; Pobelov, I.V.; Roesti, E.S.; Heath, M.D.; Skinner, M.A.;Kramer, M.F.; Martina, B.E.E.; Bachmann, M.F. Zika Virus-Derived E-DIII Protein Displayed onIm unologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement ofDengue Virus Infection. Vaccines 2019, 7, 72. [CrossRef]© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72.

The authors wish to make the following correction to their paper [...

Gustavo Cabral-Miranda

Multidisciplinary Digital Publishing Institute

Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72

https://boris.unibe.ch/148000/1/Correction%20Zika.pdf

Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72.

Abstract

Similar works

Full text

Available Versions

Bern Open Repository and Information System (BORIS)

Multidisciplinary Digital Publishing Institute